"The World Next-Generation Antibody Therapies Market will reach $2.3bn in 2015", says Visiongain

LONDON - Aug. 6, 2015 - PRLog -- A new report by visiongain predicts that the world next-generation antibody therapies market will reach $2.3bn in 2015. This forecast and others appear in Next-Generation Antibody Therapies Market Forecast 2015-2025: Opportunities for Leading Companies in ADCs, Engineered Antibodies, ALPs and Biosimilar Antibodies, published in May 2015. Visiongain is a business information provider based in London, UK.

Next-generation antibody therapies are antibodies and similar biological entities that have been specifically designed to have an enhanced mechanism of action compared to standard monoclonal antibodies. There are myriad ways in which this may occur; visiongain’s report segments the market into four segments of novel antibody therapies – antibody-drug conjugates (ADCs), engineered antibodies, bispecific antibodies, and antibody fragments and antibody-like proteins. We also include biosimilar antibodies in our coverage of this market. Rapid growth is expected in the market due to the launch of biosimilars and increasing sales of the ADCs Adcetris (brentuximab vedotin, Seattle Genetics/Millennium) and Kadcyla (ado-trastuzumab emtansine, Roche) – the two drugs that accounted for over 75% of revenues in this market in 2014.

Thomas Ling, a senior pharmaceutical and medical devices industry analyst and consultant in visiongain, said: “Next-generation antibody therapies will grow strongly in the next ten years due to increasing sales of Adcetris and Kadcyla, biosimilars, and novel engineered and bispecific antibody therapies. The pipeline for these therapies is large and growing as developers seek to improve on existing antibody therapies and Big Pharma players seek partners with innovative technology platforms and the capability to move product candidates through proof-of-concept. Cancer remains the main focus of development but other indications such as rheumatoid arthritis and psoriasis are becoming more prominent in the development pipeline.”

Visiongain’s report provides revenue forecasts to 2025 for the world next-generation antibody therapies market and leading submarkets. It forecasts sales for the antibody-drug conjugates, engineered antibodies, bispecific antibodies, and antibody fragments and antibody-like proteins segments of the market, as well as the biosimilar antibodies market. The report also discusses selected leading pipeline therapies from a pipeline of 140 unique therapies in development by over 50 companies or partners, including Big Pharma companies such as AbbVie, Allergan, Amgen, AstraZeneca, Bristol-Myers Squibb, Millennium Pharmaceuticals (Takeda), Novartis, Pfizer, Roche and Sanofi, and clinical-stage biotechs such as Ablynx, Affimed Therapeutics, Biotest, Celldex Therapeutics, Delenex Therapeutics, Glycotope, Immunomedics, MacroGenics, Merrimack Pharmaceuticals, MorphoSys, Neopharm, Seattle Genetics, TG Therapeutics and Xencor. Visiongain’s report also discusses key marketed products, commercial news, and analysis of strengths, weaknesses, opportunities and threats. It includes interviews with industry experts regarding current market trends. The report also includes a STEP analysis, providing insight into the social, technological, economic and political factors affecting this market.

Next-Generation Antibody Therapies Market Forecast 2015-2025: Opportunities for Leading Companies in ADCs, Engineered Antibodies, ALPs and Biosimilar Antibodies adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.